PCSK9 and familial hypercholesterolemia: At this purpose, the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce plasma LDL is a new approach for the treatment of hypercholesterolemia because it allows us to address the unmet clinical needs of achieving goal LDL levels for the majority of patients with high CV risk.